Search alternatives:
significant decrease » significant increase (Expand Search), significantly increased (Expand Search)
significant benefits » significant effects (Expand Search)
significant new » significant non (Expand Search), significant genes (Expand Search), significant anti (Expand Search)
significant decrease » significant increase (Expand Search), significantly increased (Expand Search)
significant benefits » significant effects (Expand Search)
significant new » significant non (Expand Search), significant genes (Expand Search), significant anti (Expand Search)
-
1
-
2
-
3
-
4
-
5
-
6
B2 decreases glycolytic intermediates in cells.
Published 2025“…The box indicates the clustering of decreased downstream glycolytic intermediates in B2-treated cells. …”
-
7
Nineteen SNPs with significant association (<i>P < </i>5 × 10<sup>−8</sup>) with risk on minJSW decrease in knee OA.
Published 2025“…<p>Nineteen SNPs with significant association (<i>P < </i>5 × 10<sup>−8</sup>) with risk on minJSW decrease in knee OA.…”
-
8
Tissue, days post-infection (dpi) and the top 10 most significant genes with increased and decreased expression with valid gene symbols for the response contrasts.
Published 2025“…<p>Tissue, days post-infection (dpi) and the top 10 most significant genes with increased and decreased expression with valid gene symbols for the response contrasts.…”
-
9
Cinacalcet administered early in the inactive phase markedly decrease parathyroid Ki-67 index.
Published 2025“…All groups were compared by Kruskal Wallis test with <i>post hoc</i> test after Dunn with Bonferroni adjustment showing significant decreased Ki-67 labeling index of <i>Cina1</i> compared to <i>Cina2</i> (p = 0.006) and the untreated CKD groups (p = 0.0001 and p = 0.0002, respectively). …”
-
10
-
11
Validation of genetic markers for risk of OA or knee OA for decrease in minJSW.
Published 2025“…The red line represents the significance threshold (<i>P < </i>5 × 10<sup>−8</sup>). …”
-
12
-
13
-
14
-
15
-
16
Data Sheet 2_Ruxolitinib synergizes with regulatory T cells to improve inflammation but has no added benefits in decreasing albuminuria in SLE.pdf
Published 2025“…No added benefit of addition of ruxolitinib is observed on the significant improvement in the urine albumin/creatinine ratio and the anti-dsDNA IgG levels induced by UCB-Tregs.…”
-
17
Data Sheet 3_Ruxolitinib synergizes with regulatory T cells to improve inflammation but has no added benefits in decreasing albuminuria in SLE.pdf
Published 2025“…No added benefit of addition of ruxolitinib is observed on the significant improvement in the urine albumin/creatinine ratio and the anti-dsDNA IgG levels induced by UCB-Tregs.…”
-
18
Data Sheet 1_Ruxolitinib synergizes with regulatory T cells to improve inflammation but has no added benefits in decreasing albuminuria in SLE.pdf
Published 2025“…No added benefit of addition of ruxolitinib is observed on the significant improvement in the urine albumin/creatinine ratio and the anti-dsDNA IgG levels induced by UCB-Tregs.…”
-
19
-
20